CN108853563B - Preparation method of absorbable suture line - Google Patents
Preparation method of absorbable suture line Download PDFInfo
- Publication number
- CN108853563B CN108853563B CN201810669285.6A CN201810669285A CN108853563B CN 108853563 B CN108853563 B CN 108853563B CN 201810669285 A CN201810669285 A CN 201810669285A CN 108853563 B CN108853563 B CN 108853563B
- Authority
- CN
- China
- Prior art keywords
- mixing
- stirring
- mass ratio
- taking
- suture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 229920001661 Chitosan Polymers 0.000 claims abstract description 8
- 102000008186 Collagen Human genes 0.000 claims abstract description 8
- 108010035532 Collagen Proteins 0.000 claims abstract description 8
- 229920001436 collagen Polymers 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims description 89
- 238000003756 stirring Methods 0.000 claims description 85
- 239000011159 matrix material Substances 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 39
- 239000011259 mixed solution Substances 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 238000002791 soaking Methods 0.000 claims description 30
- 239000000463 material Substances 0.000 claims description 25
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 21
- 238000005406 washing Methods 0.000 claims description 21
- 239000000126 substance Substances 0.000 claims description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 18
- 238000001035 drying Methods 0.000 claims description 18
- 238000002074 melt spinning Methods 0.000 claims description 16
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 14
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 claims description 14
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 14
- 239000000758 substrate Substances 0.000 claims description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000003242 anti bacterial agent Substances 0.000 claims description 12
- 239000008367 deionised water Substances 0.000 claims description 12
- 229910021641 deionized water Inorganic materials 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 12
- 239000008223 sterile water Substances 0.000 claims description 12
- 229920000520 poly(3-hydroxybutyrate-co-3-hydroxyvalerate) Polymers 0.000 claims description 8
- 229920001432 poly(L-lactide) Polymers 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 229910001870 ammonium persulfate Inorganic materials 0.000 claims description 7
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 7
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 7
- 125000004386 diacrylate group Chemical group 0.000 claims description 7
- 229960003276 erythromycin Drugs 0.000 claims description 7
- 229920000083 poly(allylamine) Polymers 0.000 claims description 7
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 239000004626 polylactic acid Substances 0.000 claims description 7
- 239000012258 stirred mixture Substances 0.000 claims description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 6
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims description 6
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 claims description 6
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 6
- 229960003260 chlorhexidine Drugs 0.000 claims description 6
- 239000002131 composite material Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000004821 distillation Methods 0.000 claims description 2
- BHTJEPVNHUUIPV-UHFFFAOYSA-N pentanedial;hydrate Chemical compound O.O=CCCCC=O BHTJEPVNHUUIPV-UHFFFAOYSA-N 0.000 claims description 2
- 238000013329 compounding Methods 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 abstract description 6
- 230000015556 catabolic process Effects 0.000 abstract description 5
- 238000006731 degradation reaction Methods 0.000 abstract description 5
- 230000017423 tissue regeneration Effects 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 230000035876 healing Effects 0.000 abstract description 3
- 230000004913 activation Effects 0.000 abstract description 2
- 239000003431 cross linking reagent Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 230000008439 repair process Effects 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 239000002585 base Substances 0.000 description 19
- 239000000047 product Substances 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000000017 hydrogel Substances 0.000 description 5
- 238000009987 spinning Methods 0.000 description 5
- REKYPYSUBKSCAT-UHFFFAOYSA-N 3-hydroxypentanoic acid Chemical compound CCC(O)CC(O)=O REKYPYSUBKSCAT-UHFFFAOYSA-N 0.000 description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical group C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-N R3HBA Natural products CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- -1 alcohol ester Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000007098 aminolysis reaction Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002729 catgut Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/06—At least partially resorbable materials
- A61L17/10—At least partially resorbable materials containing macromolecular materials
- A61L17/12—Homopolymers or copolymers of glycolic acid or lactic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/005—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters containing a biologically active substance, e.g. a medicament or a biocide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/06—At least partially resorbable materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/06—At least partially resorbable materials
- A61L17/10—At least partially resorbable materials containing macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/06—At least partially resorbable materials
- A61L17/10—At least partially resorbable materials containing macromolecular materials
- A61L17/105—Polyesters not covered by A61L17/12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
- A61L2300/206—Biguanides, e.g. chlorohexidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
- A61L2300/208—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Materials Engineering (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention discloses a preparation method of an absorbable suture, and belongs to the field of medicines. The invention improves the adhesion and the repair with cell tissues and promotes the tissue regeneration and repair by adding the cross-linking agent and simultaneously introducing the collagen and the chitosan, the activation of the cell tissues is beneficial to improving the local cell bioactivity of the suture part, and the absorption and the degradation of the absorbable suture line are promoted, thereby improving the healing effect. The invention solves the problems that the existing chemical synthesis thread is slow in absorption, is easy to cause hurting to the incised neogenetic tissue and is poor in compatibility with the organism.
Description
Technical Field
The invention belongs to the field of medicines, and particularly relates to a preparation method of an absorbable suture.
Background
The suture is one of the most basic and important materials in surgical operations, and is mainly used for hemostasis by suturing various tissues, residual cavity occlusion and tissue apposition. The medical suture belongs to one of biodegradable materials, is used for wound healing, tissue ligation and tissue fixation, and has important effect on the initial healing of the wound. Generally, the suture can be divided into two categories, namely absorbable suture and non-absorbable suture, wherein the non-absorbable suture is not degraded in vivo, and if the non-absorbable suture is not taken out, the non-absorbable suture is left in tissues as a body foreign body, so that the tissue infection is easily caused; the absorbable suture line is degraded in body tissues under the action of acid, alkali or enzyme, the degradation speed depends on the temperature and the pH value of the tissues and the liquid environment around the suture line, and the degraded products are converted into metabolites and excrement of a human body and are non-toxic and harmless. The main advantages of absorbable sutures compared to non-absorbable sutures are: non-antigenic (only slight tissue reaction on absorption); no pyrogenicity; the wound is completely healed; the stitches do not need to be removed, thereby relieving the pain of the patient and reducing the chance of inducing infection. Thus, absorbable sutures are a trend in surgical suture development. Most of the absorbable suture lines commonly used at present are catgut lines and high-molecular chemical synthetic lines, and the chemical synthetic lines are slow to absorb in actual use, so that the speed of wound recovery is not accelerated, the new tissues at the incision are easily injured, and a small amount of scars are formed. Therefore, there is a great market prospect in producing a suture that solves the above problems.
Disclosure of Invention
The technical problems to be solved by the invention are as follows: aiming at the problems that the existing chemical synthetic suture is slow in absorption, easily causes hurting injury to incised neogenetic tissues and is poor in compatibility with organisms, the preparation method of the absorbable suture is provided.
In order to solve the technical problems, the invention adopts the following technical scheme:
the preparation method of the absorbable suture line comprises the following steps:
(1) taking L-lysine hydrochloride according to a mass ratio of 7-12: adding 1, 4-butanediol into the mixture 2-4, stirring and mixing, adding camphorsulfonic acid and toluene, stirring and mixing to obtain a stirring mixture, and taking the stirring mixture according to a mass ratio of 1-5: 3-7, adding isopropanol, stirring and mixing, and distilling under reduced pressure to obtain a reduced pressure distillate;
(2) taking the reduced pressure distillate according to the mass ratio of 2-5: 3-8: 10-15, adding polyethylene glycol diacrylate and N, N-dimethylacetamide, stirring and mixing for 30-40 min to obtain a stirred mixture A, and mixing the composite antibacterial agent according to a mass ratio of 1-3: 7-10, adding triethylamine to obtain a mixed solution, and taking the stirring mixture A according to the mass ratio of 10-20: 2-5, adding the mixed solution, stirring and mixing to obtain a mixture;
(3) taking the mixture according to the mass ratio of 80-90: 10-20: 1-3, adding ammonium persulfate and tetramethylethylenediamine, stirring and mixing to obtain a matrix, soaking the matrix in acetone for 2-3 hours, taking out the matrix, washing with sterile water, and freeze-drying to obtain a freeze-dried substance for later use;
(4) taking poly-L-lactic acid according to a mass ratio of 2-5: 1-3: 10-13, adding PHBV and 1, 4-dioxane, stirring and mixing at 25-30 ℃, adding polyvinylpyrrolidone with the mass being 20-30% of that of polylactic acid, carrying out melt spinning to obtain a suture matrix, and mixing the suture matrix with the components in a mass ratio of 1: 3-5, soaking the suture thread substrate in 60% ethanol by mass, stirring and mixing, taking out the soaked suture thread substrate, and taking polyallylamine according to the mass ratio of 1-3: 9-12, adding isopropanol, stirring and mixing to obtain a soaking solution, and taking the soaked suture line matrix according to a mass ratio of 1: 5-8, adding the obtained mixture into the soaking solution for soaking, taking out the soaked substance, washing the soaked substance with sterile water, and drying to obtain a dry suture base material;
(5) taking a dry suture base material according to a mass ratio of 2-5: 8-15, adding 1% glutaraldehyde water solution by mass, standing at 25-35 ℃, taking out the soaked suture base material, drying, washing with deionized water to obtain a washed object, and taking the freeze-dried object for later use in the step (3) according to the mass ratio of 2-5: 10-15, adding deionized water, mixing to obtain a mixed solution, and mixing collagen and chitosan according to a mass ratio of 2-5: 1-3: 8-12, adding acetic acid, stirring and mixing to obtain a mixed solution a, and taking the washed objects according to the mass ratio of 10-30: 8-13: and 10-15 adding the mixed solution and the mixed solution a, standing at 2-4 ℃, filtering, taking out the spun yarn, rinsing with water, and drying to obtain the absorbable suture.
In the step (1), the addition amounts of the camphorsulfonic acid and the toluene are respectively 3-6% and 10-20% of the mass of the L-lysine hydrochloride.
The stirring conditions for stirring the mixture in the step (1) are as follows: heating to 115-125 ℃, stirring and mixing for 1-2 h.
The conditions for generating the reduced pressure distillate in the step (1) are as follows: stirring and mixing at 65-70 ℃ for 40-50 min, then preserving heat at-20 to-15 ℃ for 10-15 h, and distilling under reduced pressure to obtain the product.
The compound antibacterial agent in the step (2): benzalkonium chloride, erythromycin and chlorhexidine according to a mass ratio of 3-5: 1-3: 3-7, and mixing to obtain the product.
The stirring conditions of the substrate in the step (3) are as follows: stirring and mixing for 30-50 min at 70-80 ℃.
The melt spinning conditions in the step (5) are as follows: and (3) heating to 90-110 ℃ in a melt spinning machine for melt spinning.
Compared with other methods, the method has the beneficial technical effects that:
(1) the invention takes L-lysine hydrochloric acid and 1, 4-butanediol as raw materials to carry out polymerization reaction to form alcohol ester type monomers, then polyethylene glycol diacrylate is added, bactericidal and anti-inflammatory drugs such as benzalkonium chloride and erythromycin are loaded, the whole system forms hydrogel under the cross-linking action of ammonium persulfate and tetramethylethylenediamine free radical system, the hydrogel is loaded on the surface of a suturable line substrate, the hydrogel swells to a balance system under the action of water in blood during suturing to form a three-dimensional space network structure, can help to absorb overflowed blood to achieve the hemostatic effect, is covalently bonded with peptide ligand of a cell membrane receptor, thereby stimulating the adhesion and growth of cells in an antibacterial gel matrix and simultaneously slowly releasing the loaded antibacterial drugs, after suturing, the hydrogel can diminish inflammation and sterilize cell tissues at the local part of a wound and prevent infection, under the degradation action of human trypsin, the nano hydrogel is formed, and the human body is not damaged;
(2) the invention uses poly L-lactic acid, PHBV (copolymer of 3-hydroxybutyrate and 3-hydroxyvalerate), polyvinylpyrrolidone as base material, the poly L-lactic acid has suitable mechanical strength, good fiber flexibility, elasticity, will not cause the hurting injury to the new tissue of the incision, its knotting nature, holding the knotting and meets the requirements of clinical operation, meanwhile, the intermediate product decomposed in human body is L-lactic acid which is the normal metabolite of human body, it belongs to the endogenous active substance of human body, non-toxic, no teratogenesis possibility, but its hydrophilicity is weaker, it is not favorable for the cell to enter the pore space, adhere to and grow, the invention adds polyallylamine, the active amine group and the ester group in the added suture line matrix molecular chain carry on the aminolysis reaction, introduce hydroxy group in the aminolysis process, has improved the hydrophilic performance, at the same time, the basic performance of amine group neutralizes the carboxy group in the acid intermediate product so as to reduce the local inflammation caused by carboxy group around the implant material, the histocompatibility is improved, the heat stability in the spinning process is improved by adding PHBV (copolymer of 3-hydroxybutyrate and 3-hydroxyvalerate), an absorbable suture with better mechanical property is formed, meanwhile, the introduction of polyvinylpyrrolidone strengthens the hydrophilicity and biocompatibility of the suture, the advantage complementation is formed on a polylactic acid matrix, and the degradation rate of the absorbable suture is accelerated;
(3) the invention improves the adhesion and the repair with cell tissues and promotes the tissue regeneration and repair by adding the cross-linking agent and simultaneously introducing the collagen and the chitosan, the activation of the cell tissues is beneficial to improving the local cell bioactivity of the suture part, and the absorption and the degradation of the absorbable suture line are promoted, thereby improving the healing effect.
Detailed Description
A preparation method of absorbable suture comprises the following steps:
compound antibacterial agent: benzalkonium chloride, erythromycin and chlorhexidine according to a mass ratio of 3-5: 1-3: 3-7, and mixing to obtain the product.
Taking L-lysine hydrochloride according to a mass ratio of 7-12: 2-4, adding 1, 4-butanediol, stirring and mixing for 20-30 min, adding camphorsulfonic acid accounting for 3-6% of the mass of L-lysine hydrochloride and toluene accounting for 10-20% of the mass of L-lysine hydrochloride, heating to 115-125 ℃, stirring and mixing for 1-2 h to obtain a stirring mixture, and taking the stirring mixture according to the mass ratio of 1-5: 3-7, adding isopropanol, stirring and mixing at 65-70 ℃ for 40-50 min, then preserving heat at-20 to-15 ℃ for 10-15 h, and carrying out reduced pressure distillation to obtain a reduced pressure distillate;
(2) taking the reduced pressure distillate according to the mass ratio of 2-5: 3-8: 10-15, adding polyethylene glycol diacrylate and N, N-dimethylacetamide, stirring and mixing for 30-40 min to obtain a stirred mixture A, and mixing the composite antibacterial agent according to a mass ratio of 1-3: 7-10, adding triethylamine to obtain a mixed solution, and taking the stirring mixture A according to the mass ratio of 10-20: 2-5, adding the mixed solution, and stirring and mixing for 40-60 min to obtain a mixture;
(3) taking the mixture according to the mass ratio of 80-90: 10-20: 1-3, adding ammonium persulfate and tetramethylethylenediamine, stirring and mixing at 70-80 ℃ for 30-50 min to obtain a matrix, soaking the matrix in acetone for 2-3 h, taking out the matrix, washing with sterile water, and freeze-drying to obtain a freeze-dried product for later use;
(4) taking poly-L-lactic acid according to a mass ratio of 2-5: 1-3: 10-13, adding PHBV and 1, 4-dioxane, stirring and mixing at 25-30 ℃ for 20-30 min, adding polyvinylpyrrolidone with the mass being 20-30% of polylactic acid, heating to 90-110 ℃ in a melt spinning machine for melt spinning to obtain a suture matrix, and taking the suture matrix according to the mass ratio of 1: 3-5, soaking the suture thread substrate in 60% ethanol by mass, stirring and mixing for 2-3 h, taking out the soaked suture thread substrate, and taking polyallylamine according to the mass ratio of 1-3: 9-12, adding isopropanol, stirring and mixing for 30-40 min to obtain a soaking solution, and taking the soaked suture line matrix according to the mass ratio of 1: 5-8, adding the mixture into the soaking solution, soaking for 3-5 hours at the temperature of 30-40 ℃, taking out the soaked substance, washing the soaked substance with sterile water, and drying to obtain a dry suture base material;
(5) taking a dry suture base material according to a mass ratio of 2-5: 8-15, adding a glutaraldehyde aqueous solution with the mass fraction of 1%, standing at 25-35 ℃ for 3-4 h, taking out the soaked suture base material, drying, washing with deionized water to obtain a washed object, and taking the freeze-dried object for later use in the step (3) according to the mass ratio of 2-5: 10-15, adding deionized water, mixing to obtain a mixed solution, and mixing collagen and chitosan according to a mass ratio of 2-5: 1-3: adding acetic acid into the mixture 8-12, stirring and mixing for 30-40 min to obtain a mixed solution a, and taking the washed objects according to a mass ratio of 10-30: 8-13: 10-15, adding the mixed solution and the mixed solution a, standing at 2-4 ℃ for 18-24 h, filtering, taking out the spinning, rinsing with water, and drying to obtain the absorbable suture.
A preparation method of absorbable suture comprises the following steps:
compound antibacterial agent: benzalkonium chloride, erythromycin and chlorhexidine according to the mass ratio of 3: 1: 3, mixing to obtain the product.
Taking L-lysine hydrochloride according to a mass ratio of 7: 2, adding 1, 4-butanediol, stirring and mixing for 20min, adding camphorsulfonic acid accounting for 3% of the mass of the L-lysine hydrochloride and toluene accounting for 10% of the mass of the L-lysine hydrochloride, heating to 115 ℃, stirring and mixing for 1h to obtain a stirring mixture, taking the stirring mixture according to the mass ratio of 1: 3 adding isopropanol, stirring and mixing at 65 ℃ for 40min, preserving the temperature at-20 ℃ for 10h, and distilling under reduced pressure to obtain a reduced pressure distillate;
(2) taking the reduced pressure distillate according to the mass ratio of 2: 3: 10, adding polyethylene glycol diacrylate and N, N-dimethylacetamide, stirring and mixing for 30min to obtain a stirred mixture A, and mixing the composite antibacterial agent according to a mass ratio of 1: 7 adding triethylamine to obtain a mixed solution, and taking the stirring mixture A according to a mass ratio of 10: 2, adding the mixed solution, and stirring and mixing for 40min to obtain a mixture;
(3) taking the mixture according to the mass ratio of 80: 10: 1, adding ammonium persulfate and tetramethylethylenediamine, stirring and mixing for 30min at 70 ℃ to obtain a matrix, soaking the matrix in acetone for 2h, taking out the matrix, washing with sterile water, and freeze-drying to obtain a freeze-dried substance for later use;
(4) taking poly L-lactic acid according to the mass ratio of 2: 1: 10 adding PHBV and 1, 4-dioxane, stirring and mixing for 20min at 25 ℃, adding polyvinylpyrrolidone with the mass of 20 percent of polylactic acid, heating to 90 ℃ in a melt spinning machine for melt spinning to obtain a suture matrix, taking the suture matrix according to the mass ratio of 1: 3, soaking the suture thread substrate in 60% ethanol by mass, stirring and mixing for 2 hours, taking out the soaked suture thread substrate, and taking polyallylamine according to the mass ratio of 1: 9, adding isopropanol, stirring and mixing for 30min to obtain a soaking solution, and taking the soaked suture line matrix according to the mass ratio of 1: 5, adding the mixture into the soaking solution, soaking for 3 hours at the temperature of 30 ℃, taking out the soaked substance, washing the soaked substance by using sterile water, and drying to obtain a dry suture line base material;
(5) taking the dry suture base material according to the mass ratio of 2: 8, adding 1% glutaraldehyde aqueous solution by mass, standing at 25 ℃ for 3 hours, taking out the soaked suture base material, drying the suture base material, washing with deionized water to obtain a washed object, and taking the freeze-dried object for later use in the step (3) according to the mass ratio of 2: 10, adding deionized water, mixing to obtain a mixed solution, and mixing collagen and chitosan according to a mass ratio of 2: 1: 8, adding acetic acid, stirring and mixing for 30min to obtain a mixed solution a, and taking washings according to a mass ratio of 10: 8: 10 adding the mixed solution and the mixed solution a, standing at 2 ℃ for 18h, filtering, taking out the spinning, rinsing with water, and drying to obtain the absorbable suture.
A preparation method of absorbable suture comprises the following steps:
compound antibacterial agent: benzalkonium chloride, erythromycin and chlorhexidine according to the mass ratio of 5: 3: 7, mixing to obtain the product.
Taking L-lysine hydrochloride according to a mass ratio of 12: 4, adding 1, 4-butanediol, stirring and mixing for 30min, adding camphorsulfonic acid accounting for 6% of the mass of the L-lysine hydrochloride and toluene accounting for 20% of the mass of the L-lysine hydrochloric acid, heating to 125 ℃, stirring and mixing for 2h to obtain a stirring mixture, and taking the stirring mixture according to the mass ratio of 5: 7 adding isopropanol, stirring and mixing at 70 ℃ for 50min, preserving heat at-15 ℃ for 15h, and distilling under reduced pressure to obtain a reduced pressure distillate;
(2) taking the reduced pressure distillate according to the mass ratio of 5: 8: 15, adding polyethylene glycol diacrylate and N, N-dimethylacetamide, stirring and mixing for 40min to obtain a stirred mixture A, and mixing the composite antibacterial agent according to a mass ratio of 3: 10, adding triethylamine to obtain a mixed solution, and taking the stirring mixture A according to a mass ratio of 20: 5 adding the mixed solution, stirring and mixing for 60min to obtain a mixture;
(3) taking the mixture according to a mass ratio of 90: 20: 3 adding ammonium persulfate and tetramethylethylenediamine, stirring and mixing at 80 ℃ for 50min to obtain a matrix, soaking the matrix in acetone for 3h, taking out the matrix, washing with sterile water, and freeze-drying to obtain a freeze-dried substance for later use;
(4) taking poly-L-lactic acid according to the mass ratio of 5: 3: 13 adding PHBV and 1, 4-dioxane, stirring and mixing for 30min at 30 ℃, adding polyvinylpyrrolidone with the mass of 30 percent of polylactic acid, heating to 110 ℃ in a melt spinning machine for melt spinning to obtain a suture matrix, taking the suture matrix according to the mass ratio of 1: 5, soaking the suture thread substrate in 60% ethanol by mass for 3 hours under stirring, taking out the soaked suture thread substrate, and taking polyallylamine according to the mass ratio of 3: 12 adding isopropanol, stirring and mixing for 40min to obtain a soaking solution, and taking the soaked suture line matrix according to the mass ratio of 1: 8, adding the mixture into the soaking solution, soaking for 5 hours at 40 ℃, taking out the soaked substance, washing the soaked substance by using sterile water, and drying to obtain a dry suture line base material;
(5) taking the dry suture base material according to the mass ratio of 5: 15, adding 1% glutaraldehyde aqueous solution by mass, standing at 35 ℃ for 4 hours, taking out the soaked suture base material, drying the suture base material, washing with deionized water to obtain a washed object, and taking the freeze-dried object for later use in the step (3) according to the mass ratio of 5: 15 adding deionized water and mixing to obtain a mixed solution, and mixing collagen and chitosan according to a mass ratio of 5: 3: 12, adding acetic acid, stirring and mixing for 40min to obtain a mixed solution a, and taking washings according to the mass ratio of 30: 13: 15 adding the mixed solution and the mixed solution a, standing for 24h at 4 ℃, filtering, taking out the spinning, rinsing with water, and drying to obtain the absorbable suture.
A preparation method of absorbable suture comprises the following steps:
compound antibacterial agent: benzalkonium chloride, erythromycin and chlorhexidine according to a mass ratio of 4: 2: 5, mixing to obtain the final product.
Taking L-lysine hydrochloride according to a mass ratio of 9: 3, adding 1, 4-butanediol, stirring and mixing for 25min, adding camphorsulfonic acid accounting for 4% of the mass of the L-lysine hydrochloride and toluene accounting for 15% of the mass of the L-lysine hydrochloride, heating to 120 ℃, stirring and mixing for 1h to obtain a stirring mixture, and taking the stirring mixture according to the mass ratio of 3: 5 adding isopropanol, stirring and mixing at 67 ℃ for 45min, preserving heat at-10 ℃ for 13h, and distilling under reduced pressure to obtain a reduced pressure distillate;
(2) taking the reduced pressure distillate according to a mass ratio of 4: 5: 13 adding polyethylene glycol diacrylate and N, N-dimethylacetamide, stirring and mixing for 35min to obtain a stirred mixture A, and mixing the composite antibacterial agent according to a mass ratio of 2: adding triethylamine into the mixture 8 to obtain a mixed solution, and taking the stirred mixture A according to a mass ratio of 15: 3 adding the mixed solution, stirring and mixing for 50min to obtain a mixture;
(3) taking the mixture according to a mass ratio of 85: 15: 2 adding ammonium persulfate and tetramethylethylenediamine, stirring and mixing at 75 ℃ for 40min to obtain a matrix, soaking the matrix in acetone for 2h, taking out the matrix, washing with sterile water, and freeze-drying to obtain a freeze-dried substance for later use;
(4) taking poly-L-lactic acid according to the mass ratio of 3: 2: 12 adding PHBV and 1, 4-dioxane, stirring and mixing for 25min at 27 ℃, adding polyvinylpyrrolidone with the mass of 25 percent of polylactic acid, heating to 100 ℃ in a melt spinning machine for melt spinning to obtain a suture matrix, taking the suture matrix according to the mass ratio of 1: 4, soaking the suture thread substrate in 60% ethanol by mass, stirring and mixing for 2 hours, taking out the soaked suture thread substrate, and taking polyallylamine according to the mass ratio of 2: 10, adding isopropanol, stirring and mixing for 35min to obtain a soaking solution, and taking the soaked suture line matrix according to the mass ratio of 1: 6, adding the mixture into the soaking solution, soaking for 4 hours at 35 ℃, taking out the soaked substance, washing the soaked substance by using sterile water, and drying to obtain a dry suture line base material;
(5) taking a dry suture base material according to the mass ratio of 3: 12, adding 1% glutaraldehyde aqueous solution by mass, standing at 30 ℃ for 3 hours, taking out the soaked suture base material, drying the suture base material, washing with deionized water to obtain a washed object, and taking the freeze-dried object for later use in the step (3) according to the mass ratio of 3: 13 adding deionized water and mixing to obtain a mixed solution, and mixing collagen and chitosan according to a mass ratio of 3: 2: 10, adding acetic acid, stirring and mixing for 35min to obtain a mixed solution a, and taking washings according to the mass ratio of 20: 11: 13 adding the mixed solution and the mixed solution a, standing at 3 ℃ for 21h, filtering, taking out the spinning, rinsing with water, and drying to obtain the absorbable suture.
Comparative example: absorbable suture manufactured by a company of Guangzhou city.
Selecting the crowd: 200 patients needing operations are screened in three hospitals, wherein the patients are 15-65 years old, 100 male patients and 100 female patients, all patients voluntarily carry out the test, and follow-up visits are carried out according to the test schedule.
Experimental groups used an absorbable suture obtained by the present invention; the control group used the comparative suture, and the effect of the surgical suture use was observed and recorded for the patients. The test results are shown in Table 1.
Table 1:
| test items | Example 1 | Example 2 | Example 3 | Comparative example |
| Time to wound healing (Tian) | 13 | 12 | 13 | 15~17 |
| Number of allergic reaction cases | 0 | 0 | 0 | 1~3 |
| Suture absorption after 30 days | Is completely absorbed | Is completely absorbed | Is completely absorbed | Is partially absorbed |
| Scar condition | Is basically free of | Is basically free of | Is basically free of | With obvious scar |
In conclusion, the absorbable suture line has short wound healing time, can be completely absorbed within 30 days, avoids secondary stitch removal, has an obvious use effect superior to that of a comparative example, and can be widely used.
Claims (4)
1. A preparation method of absorbable suture is characterized by comprising the following steps:
(1) taking L-lysine hydrochloride according to a mass ratio of 7-12: 2-4, adding 1, 4-butanediol, stirring and mixing for 20-30 min, adding camphorsulfonic acid accounting for 3-6% of the mass of L-lysine hydrochloride and toluene accounting for 10-20% of the mass of L-lysine hydrochloride, heating to 115-125 ℃, stirring and mixing for 1-2 h to obtain a stirring mixture, and taking the stirring mixture according to the mass ratio of 1-5: 3-7, adding isopropanol, stirring and mixing at 65-70 ℃ for 40-50 min, then preserving heat at-20 to-15 ℃ for 10-15 h, and carrying out reduced pressure distillation to obtain a reduced pressure distillate;
(2) taking the reduced pressure distillate according to the mass ratio of 2-5: 3-8: 10-15, adding polyethylene glycol diacrylate and N, N-dimethylacetamide, stirring and mixing for 30-40 min to obtain a stirred mixture A, and mixing the composite antibacterial agent according to a mass ratio of 1-3: 7-10, adding triethylamine to obtain a mixed solution, and taking the stirring mixture A according to the mass ratio of 10-20: 2-5, adding the mixed solution, stirring and mixing to obtain a mixture;
(3) taking the mixture according to the mass ratio of 80-90: 10-20: 1-3, adding ammonium persulfate and tetramethylethylenediamine, stirring and mixing to obtain a matrix, soaking the matrix in acetone for 2-3 hours, taking out the matrix, washing with sterile water, and freeze-drying to obtain a freeze-dried substance for later use;
(4) taking poly-L-lactic acid according to a mass ratio of 2-5: 1-3: 10-13, adding PHBV and 1, 4-dioxane, stirring and mixing at 25-30 ℃, adding polyvinylpyrrolidone with the mass being 20-30% of that of polylactic acid, carrying out melt spinning to obtain a suture matrix, and mixing the suture matrix with the components in a mass ratio of 1: 3-5, soaking the suture thread substrate in 60% ethanol by mass, stirring and mixing, taking out the soaked suture thread substrate, and taking polyallylamine according to the mass ratio of 1-3: 9-12, adding isopropanol, stirring and mixing to obtain a soaking solution, and taking the soaked suture line matrix according to a mass ratio of 1: 5-8, adding the obtained mixture into the soaking solution for soaking, taking out the soaked substance, washing the soaked substance with sterile water, and drying to obtain a dry suture base material;
(5) taking a dry suture base material according to a mass ratio of 2-5: 8-15, adding 1% glutaraldehyde water solution by mass, standing at 25-35 ℃, taking out the soaked suture base material, drying, washing with deionized water to obtain a washed object, and taking the freeze-dried object for later use in the step (3) according to the mass ratio of 2-5: 10-15, adding deionized water, mixing to obtain a mixed solution, and mixing collagen and chitosan according to a mass ratio of 2-5: 1-3: 8-12, adding acetic acid, stirring and mixing to obtain a mixed solution a, and taking the washed objects according to the mass ratio of 10-30: 8-13: and 10-15 adding the mixed solution and the mixed solution a, standing at 2-4 ℃, filtering, taking out the spun yarn, rinsing with water, and drying to obtain the absorbable suture.
2. The method for preparing absorbable suture of claim 1, wherein the step (2) is carried out by compounding antibacterial agents: benzalkonium chloride, erythromycin and chlorhexidine according to a mass ratio of 3-5: 1-3: 3-7, and mixing to obtain the product.
3. The method for preparing absorbable suture of claim 1, wherein the stirring conditions of the matrix material in step (3) are as follows: stirring and mixing for 30-50 min at 70-80 ℃.
4. The method for preparing absorbable suture of claim 1, wherein the melt spinning conditions in step (4) are as follows: and (3) heating to 90-110 ℃ in a melt spinning machine for melt spinning.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810669285.6A CN108853563B (en) | 2018-06-26 | 2018-06-26 | Preparation method of absorbable suture line |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810669285.6A CN108853563B (en) | 2018-06-26 | 2018-06-26 | Preparation method of absorbable suture line |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108853563A CN108853563A (en) | 2018-11-23 |
| CN108853563B true CN108853563B (en) | 2021-03-16 |
Family
ID=64295778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810669285.6A Active CN108853563B (en) | 2018-06-26 | 2018-06-26 | Preparation method of absorbable suture line |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108853563B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110754570A (en) * | 2019-09-23 | 2020-02-07 | 中化地质矿山总局地质研究院 | Bleached fish meal and processing method and application thereof |
| CN111068100B (en) * | 2019-11-28 | 2022-07-05 | 深圳市迈捷生命科学有限公司 | Medical silk braided suture line and preparation method thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2574933C (en) * | 2004-07-26 | 2015-05-19 | Synthes (U.S.A.) | Biocompatible, biodegradable polyurethane materials with controlled hydrophobic to hydrophilic ratio |
| CN105063789A (en) * | 2013-10-30 | 2015-11-18 | 清华大学 | Absorbable suture containing PHBHHx/PLA (poly-3-hydroxybutyrate-co-3-hydroxyhexanoate/polylactic acid) |
| CN107185027A (en) * | 2017-06-07 | 2017-09-22 | 常州瑞坦商贸有限公司 | A kind of absorbable medical suture and preparation method thereof |
| CN107952107A (en) * | 2017-12-26 | 2018-04-24 | 庞振方 | A kind of absorbable medical suture |
-
2018
- 2018-06-26 CN CN201810669285.6A patent/CN108853563B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN108853563A (en) | 2018-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108744023B (en) | Silk fibroin medical biological adhesive and preparation method thereof | |
| CN108348660B (en) | Method for manufacturing high-performance suture coated with hyaluronate and high-performance suture thereof | |
| US3988411A (en) | Spinning and shaping poly-(N-acetyl-D-glucosamine) | |
| US4074366A (en) | Poly(N-acetyl-D-glucosamine) products | |
| JPH0552749B2 (en) | ||
| CN104800883A (en) | Absorbable medical suture line and preparation method thereof | |
| CN107551312B (en) | Flocculent collagen hemostatic fiber and preparation method thereof | |
| JPS60185562A (en) | Surgical prosthesis | |
| CN110448721B (en) | Antibacterial adhesive conductive hemostatic and antioxidant injectable composite hydrogel and preparation method and application thereof | |
| CN1502374A (en) | Hemostatic wound dressing containing aldehyde-modified polysaccharide | |
| CN108853563B (en) | Preparation method of absorbable suture line | |
| US3989535A (en) | Solution of poly(N-acetyl-D-glucosamine) | |
| CN101773689A (en) | Surgical repairing patch | |
| CN115926200A (en) | Preparation method and application of enzyme-catalyzed double-crosslinked polymer composite hydrogel material | |
| CN113663116A (en) | Ion-based hydrogel with hemostasis and adhesion resistance and preparation method and application thereof | |
| CN110507842B (en) | Bacterial cellulose/hyaluronic acid/epsilon-polylysine functional dressing and preparation method thereof | |
| CN113694246A (en) | Biodegradable surgical suture and preparation method thereof | |
| CN103028144B (en) | Tension-free hernia patch and preparation method thereof | |
| KR20190012958A (en) | Medicinal suture yarn coated with polydeoxyribonucleotide and method of manufacturing the same | |
| CN112870451A (en) | Nerve sheath tube and preparation method and application thereof | |
| CN115025294B (en) | Endothelialization promoting surface modification method of degradable occluder and modified degradable occluder prepared by method | |
| Afewerki et al. | Polymers for surgical sutures | |
| JP2009513290A (en) | Scleral buckling band and manufacturing method thereof | |
| KR101839538B1 (en) | Medicinal suture yarn coated with allantoin and method of manufacturing the same | |
| CN114057898B (en) | Modified cellulose and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20210302 Address after: 571200 No.14 Qifeng Road, taling New District, Dingcheng Town, Ding'an County, Haikou City, Hainan Province Applicant after: HAINAN JIANKE PHARMACEUTICAL Co.,Ltd. Address before: Room 501-4, building A2, Changzhou science and Education City, No. 18, middle Changwu Road, Wujin District, Changzhou City, Jiangsu Province, 213000 Applicant before: CHANGZHOU ENDAOZHONGQING BIOTECHNOLOGY Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP02 | Change in the address of a patent holder |
Address after: 571200 No. 14, Qifeng Road, taling new area, Dingcheng Town, Anding County, Hainan Province Patentee after: HAINAN JIANKE PHARMACEUTICAL Co.,Ltd. Address before: 571200 No.14 Qifeng Road, taling New District, Dingcheng Town, Ding'an County, Haikou City, Hainan Province Patentee before: HAINAN JIANKE PHARMACEUTICAL Co.,Ltd. |
|
| CP02 | Change in the address of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 571200 No. 14, Qifeng Road, taling new area, Dingcheng Town, Anding County, Hainan Province Patentee after: Hainan Biomaike Medical Technology Co.,Ltd. Address before: 571200 No. 14, Qifeng Road, taling new area, Dingcheng Town, Anding County, Hainan Province Patentee before: HAINAN JIANKE PHARMACEUTICAL CO.,LTD. |
|
| CP01 | Change in the name or title of a patent holder | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A preparation method of absorbable suture Effective date of registration: 20230215 Granted publication date: 20210316 Pledgee: Agricultural Development Bank of China Ding'an County Sub-branch Pledgor: Hainan Biomaike Medical Technology Co.,Ltd. Registration number: Y2023980032448 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20231030 Granted publication date: 20210316 Pledgee: Agricultural Development Bank of China Ding'an County Sub-branch Pledgor: Hainan Biomaike Medical Technology Co.,Ltd. Registration number: Y2023980032448 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right |